Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Dr. Anna Guanche, “Dr. Beauty” is One of the First in the Country to Offer Kybella™, the First and Only FDA Approved Injectable Product to Treat the “Double Chin”
  • USA - English


News provided by

Bella Skin Institute

Jun 16, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Dr Guanche preparing a Kybella injection
Dr Guanche preparing a Kybella injection

Calabasas, CA (PRWEB) June 16, 2015 -- KYBELLATM (deoxycholic acid) injection, the first and only FDA-approved injectable drug available that contours and improves the appearance of moderate to severe submental fullness, often referred to as a “double chin,” is now available in Southern California. Submental fullness is a common, yet under-treated aesthetic condition that is often resistant to diet and exercise alone and influenced by several factors, including aging, genetics and weight gain.

Now we can truly sculpt the face with a needle

Post this

“We are excited to be one of the first dermatology offices in the United States to be able to offer KYBELLA™ to patients. I have been trained on the proper technique for administering the treatment for the safety of my patients,” said CEO/Founder of Bella Skin Institute, Dr. Anna Guanche, aka Dr. “Beauty".

Each in-office treatment session with KYBELLA™ is typically 15-20 minutes. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved with KYBELLA™, re-treatment is not expected.

With this nonsurgical treatment, many patients experience visible results in two to four treatment sessions spaced at least one month apart. Up to six treatments may be administered. Treatment with KYBELLA™ is customized by Dr. Guanche to the patient’s aesthetic goals for an improved chin profile.

The most common side effects are swelling, bruising, pain, numbness, redness and formation of areas of hardness in the treatment area. In clinical trials, the incidence and severity of most side effects decreased with subsequent KYBELLA™ treatments. KYBELLA™ can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness.

KYBELLATM has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which 1,600 have been treated with KYBELLATM.

To learn more, please visit http://www.bellaskininstitute.com.

About Dr. Anna Guanche and Bella Skin Institute:
Dr. Beauty has been a sought after dermatologist to the stars for many years. Her beauty expertise has been featured on several shows such as Extra, The Doctors, and TLC’s Ten Years +Younger as she specializes in non-invasive skin rejuvenation. Dr. Beauty has been voted Super Doctor by Los Angeles Magazine and Top Doctor by Ventura Blvd Magazine for the past three years consecutively. She is a permanent columnist for Calabasas Style Magazine where she describes some of the most popular and cutting edge procedures for skin renewal and overall skin rejuvenation.

Dr. Guanche is a renowned specialist and celebrity dermatologist, who has appeared on Extra and The Doctors to share her knowledge.

The state-of-the-art Bella Skin Institute facility has been designed to be warm and engaging while focusing on providing clients with the newest, most innovative procedures available to perfect skin. We use highly advanced equipment and specialize in procedures that require little or no downtime for the convenience of our clients. Bella Skin Institute is dedicated to combining medical science and cosmetic beauty to provide each client with customized treatments to meet their needs, from dermatology services to minimally invasive cosmetic procedures, performed at the facility. Procedures performed include resurfacing, laser hair removal, Fraxel™ Ultherapy®, Velashape II, facial peels, Thermage™, mini lift, blepharoplasty and tumescent liposuction; the latest injectables including Juvéderm™ Injectable Gel, Radiesse™, Voluma™, Belotero and BOTOX® Cosmetic injections for wrinkle removal-- and now Kybella ™. Aesthetic services include SilkPeel microdermabrasion and dermalinfusion, dermaplaning; facials; and waxing. General dermatology services include skin cancer screening and surgery, acne, rashes, eczema, and more. http://www.bellaskininstitute.com

About KYBELLA™
KYBELLA™ is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin. KYBELLA™ is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat.i When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.ii

KYBELLA™ (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA™ for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Important Safety Information
What is KYBELLA™?
KYBELLA™ is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”

It is not known if KYBELLA™ is safe and effective for use outside of the submental area.

Who should not receive KYBELLA™?
You should not receive KYBELLA™ if you have an infection in the treatment area.

Before receiving KYBELLA™, tell your healthcare provider about all of your medical conditions, including if you: Have had or plan to have surgery on your face, neck, or chin; have had cosmetic treatments on your face, neck, or chin; have had or have medical conditions in or near the neck area; have had or have trouble swallowing; have bleeding problems; are pregnant or plan to become pregnant (it is not known if KYBELLA™ will harm your unborn baby); are breastfeeding or plan to breastfeed (it is not known if KYBELLA™ passes into your breast milk; talk to your healthcare provider about the best way to feed your baby if you receive KYBELLA™).

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine).

What are the possible side effects of KYBELLA™?
KYBELLA™ can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness.

The most common side effects of KYBELLA™ include: swelling, bruising, pain, numbness, redness, and areas of hardness in the treatment area.

These are not all of the possible side effects of KYBELLA™. Call your healthcare provider for medical advice about side effects.

Dr. Beauty is available for in-person or telephone interviews.
For inquiries about Kybella ™, Anna D Guanche MD, or Bella Skin Institute, please contact
[email protected] or call 818-225-0117 for more information

Ananda Fidani, Bella Skin Institute, http://www.bellaskininstitute.com, +1 818-225-0117, [email protected]

Modal title

Dr. Anna Guanche
Dr. Anna Guanche
Top Doctor -- Anna D Guanche, MD
View PDF
Top Doctor -- Anna D Guanche, MD
Super Doctor--Anna D Guanche MD
View PDF
Super Doctor--Anna D Guanche MD
Kybella reduces double-chin
Kybella reduces double-chin
Dr. Anna Guanche Top Doctor -- Anna D Guanche, MD Super Doctor--Anna D Guanche MD Kybella reduces double-chin

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.